Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer
Background: Immunotherapy combined with chemotherapy is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). However, the effect of delayed initiation of immunotherapy on its efficacy remains unclear. Objectives: This study aimed to investigate the impact of the delayed add...
Saved in:
| Main Authors: | Shuangqing Lu, Chao Wang, Xiaoyang Zhai, Zhuoran Sun, Ke Zhao, Dawei Chen, Hui Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251356919 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01) -
Addition of thoracic radiotherapy to a PD-L1 inhibitor plus chemotherapy regimen delays brain metastasis onset in extensive-stage small cell lung cancer patients without baseline brain metastasis
by: Baiyang Huang, et al.
Published: (2025-03-01) -
Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
by: Jian Zhang, et al.
Published: (2025-07-01) -
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis
by: Linjing Zhou, et al.
Published: (2025-06-01) -
Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)